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Background
Focal nodular hyperplasia is an uncommon liver tumour
that typically requires no therapeutic intervention.
Case outline
A 43-year-old woman with a 20-year history of oral con-
traceptive use presented with symptomatic bilateral liver
masses. Biopsy revealed hepatocellular carcinoma in the
right hemiliver and focal nodular hyperplasia in the left
hemiliver. At operation, the patient was noted to have mul-
tiple liver nodules bilaterally, and all intraoperative biopsies
were consistent with focal nodular hyperplasia including a
biopsy taken from the region that demonstrated carci-
noma preoperatively. Because of the earlier biopsy results
and the patient’s preoperative symptoms, a right hemihep-
atectomy was performed. Final pathology revealed hepato-
cellular carcinoma directly adjacent to an area of focal
nodular hyperplasia, as well as multiple other areas of
hyperplastic liver tumour.
Discussion
Although focal nodular hyperplasia is believed to be benign,
few studies have followed patients with this tumour beyond
three years. Longer-term follow-up studies are needed to
determine the natural history of focal nodular hyperplasia,
potentially focussing on a subset of patients with either
diffuse tumours or prolonged oral contraceptive use.
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Introduction
Focal nodular hyperplasia (FNH) is a rare hepatic tumour
comprising hyperplastic liver parenchyma, predominantly
affecting women of late reproductive age [1–6]. While
lesions have been found simultaneously in rare cases of
fibrolamellar carcinoma and in a single case of hepatocel-
lular carcinoma, FNH is generally considered a benign
tumour with no malignant potential. We report the case of
a 43-year-old woman with diffuse FNH and a hepatoma
directly contiguous to an area of FNH.
Case Report
A 43-year-old woman presented with recent right upper
quadrant pain and right shoulder pain. Initial work-up
included an ultrasound scan, which demonstrated a mass
lesion in the liver, and a CT scan, which revealed a large
lesion in the right lobe of her liver as well as a smaller mass
in the left lobe. The remainder of the liver appeared inho-
mogeneous with intact vasculature. 
The patient had hepatitis A as a child. In addition, she
had been on oral contraceptives for 20 years. She took no
medicines. Physical examination was entirely within nor-
mal limits. Laboratory rests showed elevations in plasma
levels of alkaline phosphatase to 161 IU/L and aspartate
aminotransferase to 146 IU/L. Her haematocrit was mildly
decreased at 34.7%. Coagulation studies, platelets, white
blood cell count, electrolytes, bilirubin, and albumin were
all within normal limits. Alpha fetoprotein was mildly ele-
vated at 13 ng/ml. CT-guided needle biopsy revealed hepato-
cellular carcinoma in the mass in her right lobe and FNH
in the left lobe mass.
At abdominal exploration, the patient was noted to
have multiple liver nodules bilaterally with a gross appear-
ance characteristic of FNH. Frozen section biopsies were
taken from the dominant lesion in each lobe (consistent
with the two masses noted on CT scan) as well as from the
falciform ligament. All were reported to contain FNH
without histological evidence of malignancy. In view of the
patient’s history of pain secondary to the tumour in the
right lobe of liver as well as the preoperative tissue diagno-
sis, a right hemihepatectomy was performed. The patient
had an unremarkable hospital course and was discharged to
home on the eighth postoperative day.
Gross pathology revealed an 18 3 15 3 9 cm sized right
hemiliver. The most striking feature was a 7 3 6.5 3 3.5 cm
area composed of a collection of light tan nodules. These
smaller nodules ranged from 0.3 to 3 cm in maximal dimen-
sion. Focal areas of haemorrhagic necrosis were noted in
the centre of this area. Separate from this dominant area
there were widely scattered, multiple nodules up to 1.5 cm
in size, located in otherwise normal liver parenchyma.
Microscopically, the area of nodular aggregates showed
moderately differentiated hepatocellular carcinoma.
Focally, there was marked cytologic atypia with bizarre,
enlarged nuclei, as well as multiple atypical mitotic figures.
An area of parenchyma immediately adjacent to the hepa-
tocellular carcinoma nodules demonstrated bile duct prolif-
eration and moderate chronic inflammation (Figure 1).
Surgical margins were free from tumour.
Multiple other nodules showed hyperplastic tissue with
bile duct proliferation similar to that found adjacent to the
tumour described above. These lesions were consistent with
FNH. The liver parenchyma surrounding these areas of
FNH was normal. A single lymph node and the gallbladder
were also free from tumour. The final stage of the tumour
was T3N0M0, with multiple foci of FNH in otherwise
uninvolved liver.
A routine MRI scan obtained three months postopera-
tively to follow disease progression demonstrated a new 6
cm mass in the medial segment of the left lobe of liver. CT-
guided biopsy revealed recurrent hepatocellular carcinoma.
As part of an evaluation to determine the patient’s candi-
dacy for possible liver transplantation, a chest CT revealed
an indeterminate 5 mm nodule in the right lower lobe
(superior segment). Thoracoscopic biopsy of this lesion
revealed metastatic hepatocellular carcinoma. The patient
subsequently underwent chemoembolisation of her liver six
months postoperatively. Some decrease was noted in the
degree of liver disease; however, she rapidly developed
multiple new pulmonary metastases. The patient was then
offered systemic chemotherapy as part of a clinical trial
with doxil and gemcitabine but has subsequently been lost
to follow-up.
Discussion
FNH is a well-circumscribed liver tumour typically grossly
comprising of a central fibrous scar surrounded by hyper-
plastic nodules [3,4,7,8]. Histologically, the arterial and
venous channels in the fibrous body are accompanied by
proliferating bile ducts [9,10]. The pathogenesis of FNH
continues to be controversial, with various authors consid-
ering the entity to be a neoplasm, a hamartoma, or a
response to either ischaemia, focal injury, or to a congeni-
tal abnormality of portal tracts [2–4,10–12]. No clear aeti-
ology in the development of FNH has been identified. Oral
contraceptive use has been implicated, but this remains
controversial [13–17].
Initially classified in 1958, more than 80% of FNH
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Figure 1. (a) Haematoxylin and eosin (H&E)-stained section shows hepatocellular carcinoma (large arrow) directly adjacent to areas of FNH (small arrow). (b)
Higher power section showing FNH on the left and hepatocellular carcinoma on the right.
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lesions are solitary and less than 5 cm in diameter [3,7,9].
Most lesions exhibit no growth over time, and haemor-
rhage into nodules is exceedingly rare [7,18]. Since FNH is
typically asymptomatic, little information on its long-term
natural history is available. A recent study by Mathieu et
al., following 136 women with FNH via serial MRIs for an
average follow-up of 25 months, showed change in tumour
size in only four patients [17]. Another series of 53 patients
with FNH, monitored with multimodality radiological
studies, showed no evidence of malignancy in a mean fol-
low-up of 32 months, with an increase in tumour size in five
patients and a decrease in tumour size in two patients [19].
These results contrast with an earlier report in which 16
patients with FNH were followed with ultrasound for a
mean follow-up of 33 months. Tumour size was unchanged
in only half the patients, tumour size was reduced in seven
patients, and tumour disappearance was noted in one
patient [20]. The alterations in tumour size in all studies
were independent of oral contraceptive use.
While simultaneous occurrence of FNH with fibro-
lamellar carcinoma has been rarely described [21–23], FNH
is believed to have no potential for malignant degenera-
tion. The sole previous report of hepatocellular carcinoma
and FNH co-existing in a patient demonstrated that the
tumours had separate clonal origin [24]. The combination
of a presumed benign natural history without fear of dedif-
ferentiation has led to expectant management being the
mainstay of FNH therapy. Surgery is reserved for sympto-
matic patients, although some sources advocate operating
for lesions that enlarge due to oral contraceptives
[1,6,19,25–29]. In addition, despite multimodality imaging
techniques including ultrasound, dynamic CT, SPECT,
MRI, 99T-sulphur colloid scan, cholescintigraphy, and
positron emission tomography, FNH may be difficult to
differentiate from hepatic adenoma or adenocarcinoma
preoperatively [6,17,28,30–34].
This case demonstrates the first reported example of
hepatocellular carcinoma arising in a liver with diffuse
FNH. Notably, an area of FNH was found directly adjacent
to the cancer on pathological examination. Although the
two lesions were directly contiguous, there is no evidence
that the cancer arose directly from the area of FNH. With-
out the benefit of following this lesion radiographically or
histologically over time, there is no way of knowing if a
FNH lesion underwent malignant degeneration. Nonethe-
less, it is intriguing that the cancerous tumour was sur-
rounded by areas of FNH. This intimate association is
underscored by the intraoperative frozen section biopsy of
the tumour site. Although performed under direct vision,
Tru-cut® biopsy still showed only FNH in the area where a
hepatoma was eventually diagnosed on final pathology. 
The findings seen in this patient demonstrate the
importance of gaining a more complete understanding of
the natural history of FNH. To date, only a few studies fol-
lowing patients with FNH for two to three years have been
performed [17,20,35]. Perhaps certain subsets of patients
with FNH have an incidence of malignant degeneration.
Certainly, the patient described had a more severe and dif-
fuse case of FNH than is typically described, which might
lead to a more aggressive phenotype over time. In addition,
she had a 20-year history of oral contraceptive use. While
the relationship between contraception and FNH is far
from clear [13–17], prolonged usage may represent a risk
factor for growth or eventual malignant transformation.
Based on the available data, conservative therapy for
patients with FNH continues to be appropriate. Although
operative excision may be performed safely with minimal
morbidity, symptomatic FNH continues to be the only
clear indication for this procedure. Nonetheless, this
patient poses a possible challenge to the idea that all FNH
lesions — regardless of size and prolonged oral contracep-
tive use — are benign lesions. Further multimodal study of
the natural history of this disease is thus warranted to
assess the malignant potential of FNH and possible alter-
ations to accepted treatment protocols.
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